KOPRAN
|
|
BOM : 524280     NSE : KOPRAN     | |
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive] Debt : Average |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Downward Pledged Shares : None or < 25% |
Jun 24,2022 |
Price(EOD): ₹ 192.75
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 929.06 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
KOPRAN | 5.5% | -13.5% | -4.8% |
SUN PHARMACEUTICAL INDUSTRIES | 2.4% | -8.5% | 23.8% |
DIVIS LABORATORIES | 4.3% | 6.7% | -12.6% |
DR REDDYS LABORATORIES | 3.8% | 0% | -18.7% |
CIPLA | 0.8% | -3.2% | -2.4% |
GLAND PHARMA | 2.4% | -7.3% | -17.9% |
PIRAMAL ENTERPRISES | 3.9% | -11% | -33.4% |
CADILA HEALTHCARE | 5.7% | -5.1% | -45.1% |
TORRENT PHARMACEUTICALS | 4.1% | -0.9% | -2.5% |
FUNDAMENTAL ANALYSIS OF KOPRAN
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF KOPRAN
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
13.54
P/E Calculated based on EPS of 14.24
[ Mar2021 - Consolidated Results ] 3.4
P/B Calculated based on Book Value of 56.65
[ Mar2021 - Consolidated Results ] 1.95
P/S Calculated based on Revenues of 477.522 Cr
[ TTM - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
65% 136% 270% |
SHARE PRICE MOMENTUM OF KOPRAN
KOPRAN vs SENSEX
DEBT OF KOPRAN
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2021 2020 2019 Avg_3yrs |
0.06 0.2 0.23 0.16 |
0.27 0.47 0.58 0.44 |
[Last Annual Data : Mar2021]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF KOPRAN
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Mar2022 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF KOPRAN
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
8.37% -0.59% -9.64% -12.75% |
2.11% 39.37% 18.96% 16.41% |
QtrlyTrend |
2 | |
Latest Qtr: Mar2022 | ||
Quarterly Result Analysis → |
KOPRAN related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE HEALTHCARE | 3.1% | -1.8% | -13% |
S&P BSE ALLCAP | 2.5% | -2% | -0.8% |
S&P BSE MIDSMALLCAP | 2% | -1.4% | -2% |
S&P BSE SMALL CAP | 1.6% | -2.4% | -1.3% |
You may also like the below Video Courses
FAQ about KOPRAN
Is KOPRAN good for long term investment?
As on Jun 24,2022, the Fundamentals of KOPRAN look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of KOPRAN . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is KOPRAN UnderValued or OverValued?
As on Jun 24,2022, KOPRAN is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of KOPRAN ?
As on Jun 24,2022, the Intrinsic Value of KOPRAN is Rs. 81.52 determined based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 116.96
Fair Value [Median EV / Sales Model] : Rs. 81.52
Fair Value [Median Price / Sales Model] : Rs. 52.14
Median Fair Value of KOPRAN : Rs. 81.52
Is KOPRAN trading at a Premium or Discount?
As on Jun 24,2022, KOPRAN is trading at a Premium of 136% based on the estimates of Median Intrinsic Value!SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs DR REDDYS LABORATORIES LTD
CIPLA LTD vs GLAND PHARMA LTD vs PIRAMAL ENTERPRISES LTD
CADILA HEALTHCARE LTD vs TORRENT PHARMACEUTICALS LTD vs ALKEM LABORATORIES LTD
LUPIN LTD vs AUROBINDO PHARMA LTD vs BIOCON LTD
ABBOTT INDIA LTD vs LAURUS LABS LTD vs IPCA LABORATORIES LTD
